Clinical TrialMay 14, 2026, 08:32 AM
GT Biopharma Doses First Patient in Phase 1 Trial for GTB-5550
AI Summary
GT Biopharma, a clinical stage immuno-oncology company, announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550. This B7-H3-targeted natural killer (NK) cell engager is the third TriKE to enter clinical development, marking an expansion into broader solid tumor opportunities. The trial will initially focus on prostate cancer patients during dose escalation and will later expand to evaluate up to seven additional tumor types. GTB-5550 is also the first nanobody TriKE to be tested with patient-friendly subcutaneous dosing, with updates expected in the second half of 2026.
Key Highlights
- GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550.
- GTB-5550 is the 3rd TriKE to enter clinical development, expanding into solid tumors.
- The Phase 1a dose escalation will primarily enroll prostate cancer patients.
- Phase 1b expansion will evaluate GTB-5550 in 7 tumor types.
- GTB-5550 is the first nanobody TriKE tested with subcutaneous dosing.
- Company anticipates providing updates on trial progress in 2H 2026.
- Trial details are available on clinicaltrials.gov with identifier NCT07541573.
Price Impact
More from GTBP